Roche enters $1.15B partnership with Sarepta

Monday, 23. December 2019 07:47

Swiss pharmaceutical company Roche Holding AG announced on Monday it has entered a licencing agreement with Sarepta Therapeutics Inc. for the right to launch and commercialize SRP-9001, Sarepta's gene therapy for Duchenne muscular dystrophy (DMD) outside the United States territory.

Under the agreed terms, Sarepta will get an upfront payment of $750 million in cash and $400 million in equity. Also, the company is qualified for receiving regulatory and sales milestones as well as royalties on net sales.

James Sabry, head of Roche Pharma Partnering said that they are "excited to enter this licensing agreement with Sarepta. By working together to provide SRP-9001 to patients, we hope to fundamentally transform the lives of patients and families living with this devastating disorder for which there are currently only limited treatment options."

Related Links: Roche Holding
Author:
Breaking the News / TF